PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability.
Publication
, Journal Article
Mark, DB; Schulman, KA
Published in: JAMA
August 22, 2017
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
August 22, 2017
Volume
318
Issue
8
Start / End Page
711 / 712
Location
United States
Related Subject Headings
- Serine Endopeptidases
- Proprotein Convertases
- Humans
- General & Internal Medicine
- Cholesterol, LDL
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Mark, D. B., & Schulman, K. A. (2017). PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA, 318(8), 711–712. https://doi.org/10.1001/jama.2017.8907
Mark, Daniel B., and Kevin A. Schulman. “PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability.” JAMA 318, no. 8 (August 22, 2017): 711–12. https://doi.org/10.1001/jama.2017.8907.
Mark DB, Schulman KA. PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA. 2017 Aug 22;318(8):711–2.
Mark, Daniel B., and Kevin A. Schulman. “PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability.” JAMA, vol. 318, no. 8, Aug. 2017, pp. 711–12. Pubmed, doi:10.1001/jama.2017.8907.
Mark DB, Schulman KA. PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA. 2017 Aug 22;318(8):711–712.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
August 22, 2017
Volume
318
Issue
8
Start / End Page
711 / 712
Location
United States
Related Subject Headings
- Serine Endopeptidases
- Proprotein Convertases
- Humans
- General & Internal Medicine
- Cholesterol, LDL
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences